Free Trial
ASX:NEU

Neuren Pharmaceuticals (NEU) Stock Price, News & Analysis

Neuren Pharmaceuticals logo

About Neuren Pharmaceuticals Stock (ASX:NEU)

Advanced Chart

Key Stats

Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
57,935 shs
Average Volume
N/A
Market Capitalization
$1.68 billion
P/E Ratio
14.31
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neuren Pharmaceuticals Limited, a biopharmaceutical company, develops drugs for the treatment of neurological disorders. It develops and commercializes DAYBUE (trofinetide), which has been registered to treat Rett syndrome in adults and pediatric patients 2 years of age and older, as well as in Phase 2 clinical trial to treat Fragile X syndrome. The company also develops NNZ-2591, which has completed Phase 2 clinical trial for the treatment of Phelan-McDermid, and in Phase 2 clinical trial for the treatment of Angelman, Pitt Hopkins, and Prader-Will syndromes. In addition, it provides development services; and holds loan funded shares. The company was incorporated in 2001 and is based in Camberwell, Australia.

Receive NEU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neuren Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter.

NEU Stock News Headlines

Trump to redistribute trillions of dollars
Seeing how the media and other analysts are covering Trump’s actions – it’s laughable. At least it would be laughable if it wasn’t putting so many Americans’ financial futures at severe risk… That’s why, with the 100-day mark of Trump’s second term just days away, it’s time to shine a light on what’s really going on, because if you move your money out of the wrong places and into the right ones before it’s too late… …you could be one of the few who profits from this imminent trillion-dollar reset.
See More Headlines

NEU Stock Analysis - Frequently Asked Questions

Neuren Pharmaceuticals Limited (ASX:NEU) released its quarterly earnings results on Wednesday, February, 27th. The company reported $0.03 EPS for the quarter. Neuren Pharmaceuticals had a trailing twelve-month return on equity of 55.28% and a net margin of 60.67%.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neuren Pharmaceuticals investors own include Oxford Lane Capital (OXLC), Pilbara Minerals (PLS), Sunrise Energy Metals (SRL), Westpac Banking (WBC), FBR (FBR), Embark Early Education (EVO) and Dream Industrial Real Estate Investment Trust (DREUF).

Company Calendar

Last Earnings
2/27/2019
Today
5/08/2025

Industry, Sector and Symbol

Stock Exchange
ASX
Sector
Medical
Industry
Biotechnology
Sub-Industry
Chemicals
Current Symbol
ASX:NEU
CIK
N/A
Fax
N/A
Employees
2,060
Year Founded
N/A

Profitability

Trailing P/E Ratio
14.31
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$117.29 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$193.34 million
Price / Cash Flow
12.46
Book Value
A$1.72 per share
Price / Book
N/A

Miscellaneous

Free Float
N/A
Market Cap
$1.68 billion
Optionable
Not Optionable
Beta
2.13
7 Stocks That Could Be Bigger Than Tesla, Nvidia, and Google Cover

Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.

Get This Free Report

This page (ASX:NEU) was last updated on 5/8/2025 by MarketBeat.com Staff
From Our Partners